Literature DB >> 9699697

Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites.

P D Harvey1, E Howanitz, M Parrella, L White, M Davidson, R C Mohs, J Hoblyn, K L Davis.   

Abstract

OBJECTIVE: Although many geriatric patients with schizophrenia have been referred to nursing home care, little is known about their characteristics. Across nursing home and chronic hospital settings, the authors directly assessed poor outcome geriatric patients with schizophrenia and contrasted their cognitive, symptomatic, and adaptive functioning to that of acutely admitted patients with a better outcome over the lifetime course of the illness.
METHOD: The subjects were 97 chronically hospitalized patients with schizophrenia, 37 patients with chronic schizophrenia who lived in nursing homes, and 31 acutely admitted geriatric patients with schizophrenia. These patients were rated with the Positive and Negative Syndrome Scale, tested with a neuropsychological battery, evaluated with the Mini-Mental State examination, and rated on a scale of social and adaptive deficits, the Social Adaptive Functioning Evaluation scale.
RESULTS: Each group of patients proved discriminable from the other two: nursing home patients displayed the most severe adaptive deficits, and acutely admitted patients were the least cognitively impaired. Cognitive impairment was the strongest predictor of adaptive deficits for all three groups, and negative symptom differences among the groups were smaller than differences in cognitive impairment. Nursing home patients had the least severe positive symptoms, and the acutely ill and chronic hospital patients did not differ on positive symptoms.
CONCLUSIONS: Cognitive impairment is a predictor of both overall outcome and specific adaptive deficits. These data suggest that interventions aimed at cognitive impairment may have an impact on overall functional status. In comparison, positive symptom severity is less strongly correlated with overall adaptive outcome and is uncorrelated with specific deficits in adaptive skills.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9699697     DOI: 10.1176/ajp.155.8.1080

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  66 in total

1.  Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia.

Authors:  Pavel Katsel; William Byne; Panos Roussos; Weilun Tan; Larry Siever; Vahram Haroutunian
Journal:  Neuropsychopharmacology       Date:  2011-01-26       Impact factor: 7.853

Review 2.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

3.  Cognition in schizophrenia: from basic science to clinical treatment.

Authors:  Philip D Harvey; Mark A Geyer; Trevor W Robbins; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2003-08-30       Impact factor: 4.530

4.  Impact of serious mental illness online training for certified nursing assistants in long term care.

Authors:  Victor Molinari; John V Hobday; Rosalyn Roker; Mark E Kunik; Rosalie Kane; Merrie J Kaas; Chandra Mehrotra; Christine L Williams; Joyce C Robbins; Debra Dobbs
Journal:  Gerontol Geriatr Educ       Date:  2016-09-22

Review 5.  Very poor outcome schizophrenia: clinical and neuroimaging aspects.

Authors:  Serge A Mitelman; Monte S Buchsbaum
Journal:  Int Rev Psychiatry       Date:  2007-08

Review 6.  Real-world cognitive--and metacognitive--dysfunction in schizophrenia: a new approach for measuring (and remediating) more "right stuff".

Authors:  Danny Koren; Larry J Seidman; Morris Goldsmith; Phillip D Harvey
Journal:  Schizophr Bull       Date:  2006-01-05       Impact factor: 9.306

Review 7.  Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia.

Authors:  David A Lewis; Takanori Hashimoto; Harvey M Morris
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

8.  The involvement of Type II Neuregulin-1 in rat visuospatial learning and memory.

Authors:  Adam R Taylor; Sara B Taylor; James I Koenig
Journal:  Neurosci Lett       Date:  2012-10-23       Impact factor: 3.046

9.  Should cognitive impairment be included in the diagnostic criteria for schizophrenia?

Authors:  Richard S E Keefe
Journal:  World Psychiatry       Date:  2008-02       Impact factor: 49.548

10.  Right-hemisphere encephalopathy in elderly subjects with schizophrenia: evidence from neuropsychological and brain imaging studies.

Authors:  V S Gabrovska-Johnson; M Scott; S Jeffries; N Thacker; R C Baldwin; A Burns; S W Lewis; J F W Deakin
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.